Silencing RSAD2 in B cells from patients with primary Sjögren’s syndrome attenuates their hyperactivation via suppression of the NF-κB pathway, suggesting its potential as a therapeutic target [42]. Here, NFKB1 is linked to Sjogren syndrome.